Manama, November 14 / BNA / The National Health Regulatory Authority (NHRA) today approved the emergency use of the drug Evoshield to combat the Covid-19 virus, making Bahrain the first country to use the drug.
The drug will be available to adults 18 years of age and older, who are immunocompromised or who are taking immunosuppressive medications, or to individuals who have occupations that put them at risk.
The decision follows an evaluation of data provided by manufacturer AstraZeneca, which was carried out by the NHRA’s Pharmaceutical Products Regulatory Division.
EVUSHELD, consisting of a combination of two antibodies, achieved a “statistically significant reduction in the incidence of acute or fatal COVID-19 infection” in non-hospitalized patients with mild to moderate symptoms.
AOQ